EUVIMEDEUVIMED entdecken
Crossref

Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type

Frédérique Audic, Sonia M Dubois, Julien Durigneux, Christine Barnerias, Arnaud Isapof, Marie-Christine Nougues, Jean-Baptiste Davion, Christian Richelme, Carole Vuillerot, Laure Legoff, Pascal Sabouraud, Claude Cances und 15 weitere

Archives de Pédiatrie · 2024-02 · 31 (2) · 117-123

DOI: 10.1016/j.arcped.2023.10.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives de Pédiatrie, 2024-02. Verfasst von Frédérique Audic und 26 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 1338…. Hauptthemen laut MEDLINE: DNA Copy Number Variations, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder due to an autosomal recessive mutation in the survival motor neuron 1 gene (SMN1), causing degeneration of the anterior horn cells of the spinal cord and resulting in muscle atrophy. This study aimed to report on the 36-month follow-up of children with SMA treated with nusinersen before the age of 3 years. Changes in motor function, nutritional and ventilatory support, and orthopedic outcomes were evaluated at baseline and 36 months after intrathecal administration of nusinersen and correlated with SMA type and SMN2 copy number. RESULTS: We found that 93% of the patients gained new motor skills during the 3 years-standing without help for 12 of 37 and walking with help for 11 of 37 patients harboring three SMN2 copies. No patients with two copies of SMN2 can stand alone or walk. Patients bearing three copies of SMN2 are more likely to be spared from respiratory, nutritional, and orthopedic complications than patients with two SMN2 copies. CONCLUSION: Children with SMA treated with nusinersen continue to make motor acquisitions at 3 years after initiation of treatment. Children with two SMN2 copies had worse motor, respiratory, and orthopedic outcomes after 3 years of treatment than children with three copies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Copy Number VariationsMuscular Atrophy, SpinalChild, PreschoolHumansMutationOligonucleotidesSurvival of Motor Neuron 2 Protein

Stichwörter der Autor:innen

NusinersenSMN2Spinal muscular atrophy

Substanzen

nusinersenOligonucleotidesSMN2 protein, humanSurvival of Motor Neuron 2 Protein

Autor:innen und Institutionen

  • Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France. Electronic address: frederique.audic@ap-…
  • Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France.
  • Centre de Référence des Maladies Neuromusculaires AOC, CHU d'Angers, Angers, France.
  • Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neurologie pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France.
  • Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neuropédiatrie, Hôpital Trousseau, APHP, Paris, France.
  • Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neuropédiatrie, Hôpital Salengro CHU Lille, Lille, France.

Zitieren

APA

Audic, F., Dubois, S. M., Durigneux, J., Barnerias, C., Isapof, A., Nougues, M. C., Davion, J. B., Richelme, C., Vuillerot, C., Legoff, L., Sabouraud, P., Cances, C., Laugel, V., Ropars, J., Espil-Taris, C., Trommsdorff, V., Pervillé, A., Garcia-de-la-Banda, M. G., Testard, H., …, & Desguerre, I. (2024). Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type. Archives de Pédiatrie, 31(2), 117-123. https://doi.org/10.1016/j.arcped.2023.10.009

Vancouver

Audic F, Dubois SM, Durigneux J, Barnerias C, Isapof A, Nougues MC, et al. Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type. Archives de Pédiatrie. 2024;31(2):117-123. doi:10.1016/j.arcped.2023.10.009

BibTeX
@article{Audic2024,
  author = {Audic, Frédérique and Dubois, Sonia M and Durigneux, Julien and Barnerias, Christine and Isapof, Arnaud and Nougues, Marie-Christine and Davion, Jean-Baptiste and Richelme, Christian and Vuillerot, Carole and Legoff, Laure and Sabouraud, Pascal and Cances, Claude and Laugel, Vincent and Ropars, Juliette and Espil-Taris, Caroline and Trommsdorff, Valérie and Pervillé, Anne and Garcia-de-la-Banda, Marta Gomez and Testard, Hervé and Chouchane, Mondher and Walther-Louvier, Ulrike and Schweizer, Cyril and Halbert, Cécile and Badri, Myriam and Quijano-Roy, Susana and Chabrol, Brigitte and Desguerre, Isabelle},
  title = {Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type},
  journal = {Archives de Pédiatrie},
  year = {2024},
  volume = {31},
  number = {2},
  pages = {117--123},
  doi = {10.1016/j.arcped.2023.10.009}
}
Kostenlos starten →